Fig. 2

CSF metabolites differ between patients with GBM and controls. (A) sPLS-DA plot with the 31 GBM samples shows that GBM samples collected pre-treatment and post-treatment cluster in separate groups. (B) Volcano plot comparing CSF metabolites in CSF from GBM pre-treatment vs. GBM post-treatment. Colored points represent metabolites that are present at significantly different levels and fold change (-log10(p-value) > 1.3, log2(Post/Pre) > + 1 or < -1) in CSF samples from GBM pre-treatment vs. GBM post-treatment. Several CSF metabolites are present at significantly different levels in GBM pre-treatment compared to GBM post-treatment. P-value and fold change for differentially abundant metabolites are listed in Supplementary Material 5. (C) sPLS-DA plot with the GBM pre-treatment (n = 13) and control (n = 13) CSF samples shows that GBM and control samples cluster in separate groups. (D) Supervised heat map of metabolite levels (n = 125) in CSF samples from patients with GBM (n = 31) and controls (n = 13). GBM patients either had CSF collected pre-treatment (n = 13) or post-treatment (n = 18). (E) Volcano plot comparing CSF metabolites in CSF from GBM vs. controls. Colored points represent metabolites that are present at significantly different levels and fold change (-log10(p-value) > 1.3, log2(GBM/Control) > + 1 or < -1) between GBM and control CSF samples. Seven metabolites are present at significantly higher levels in the CSF of GBM patients